Mayo Clinic

The partners are developing and optimizing an algorithm that assesses the likelihood of a patient's cancer progressing to metastasis.

The alliance joins WuXi AppTec's laboratory and manufacturing services with Mayo Medical Laboratories' clinical and lab testing expertise.

The sepsis diagnostics market heated up during the year, with FDA clearances for a handful of tests, growing investor interest, and R&D advances in the field.

The Mayo Clinic will apply PathoQuest's next-generation sequencing-based iDtect Blood test in a study to identify febrile neutropenia in patients.

The deal enables Mayo Clinic to serve as a US-based testing center for physicians and scientists interested in evaluating four blood-based assays.

The firm's CEO said that the test must undergo additional clinical studies, but it could be available from a CLIA-certified lab in about a year and a half.

The firm's transplant allograft status test identifies genetic biomarkers that predict the likelihood of a patient's immune system to reject the organ over time.

The company recently released the MGISEQ-2000, MGISEQ-200, and MGIFLP sequencing platforms, as well as the MGIUS-R3 robotic ultrasound system.

Hospitals are increasingly recognizing the impact that improper lab test ordering can have on costs and patient care, doctors said.

Laboratories are developing mitigation strategies to raise awareness that biotin supplements may be interfering with some patient test results.

Pages